HCM
ABBV icon

Highview Capital Management’s AbbVie ABBV Stock Holding History

Highview Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,915
Closed -$873K – 106
2024
Q4 		$873K Sell
4,915
-218
-4% -$40.1K 0.34% 76
2024
Q3 		$1.01M Buy
5,133
+217
+4% +$40.5K 0.41% 68
2024
Q2 		$843K Sell
4,916
-160
-3% -$26.5K 0.35% 75
2024
Q1 		$924K Buy
+5,076
New +$875K 0.42% 69

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Highview Capital Management's ABBV Position: Q1 2025 in Review

Highview Capital Management sold out of AbbVie (ABBV) in Q1 2025, closing a stake of 4,915 shares — an estimated $873K sold.

Highview Capital Management first reported a position in ABBV in Q1 2024 and held it in 4 quarters. The position peaked at $1.01M in Q3 2024. 3,819 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.

  • Highview Capital Management reported no remaining AbbVie position as of Q1 2025 after selling out during the quarter.
  • Highview Capital Management sold 4,915 AbbVie shares in Q1 2025, an estimated $873K.
  • Highview Capital Management first reported a position in AbbVie in Q1 2024 and held it in 4 quarters.
  • Highview Capital Management's AbbVie position peaked at $1.01M in Q3 2024.
  • 3,819 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.

Based on Highview Capital Management's 13F filing for Q1 2025, filed 30 Apr 2025.